Are Patients Being Misled About Cholesterol-lowering Drugs

Lipitor by Pfizer.

| Jun 25, 2013

The main question that doctors---and patients---ask about a prescription drug is simple: Does it work? Does this medicine improve the condition it's prescribed for?

In one recent case, the answer seems to be "No." A new report in The Journal of the American Medical Association has raised the alarm about fibrates, first-line therapy. "This is a classical example of marketing triumphing over science," said Dr. Steven Nissen, cardiovascular medicine chair at the Cleveland Clinic Foundation, in an interview with ABC News.

Fibrates predate statins, the most widely prescribed cholesterol-lowering drugs. (The best-known statin remains Lipitor, manufactured and marketed by Pfizer.) While fibrates reduce bad cholesterol and increase good cholesterol modestly, they're most effective at reducing triglycerides.

Doctors have increasingly turned to fibrates. From 2002 to 2009, prescriptions of the drugs increased by 117 percent in the United State. Their slice of the cholesterol medicine market remains modest, though---just 9.4 percent.

So what's the problem? According to studies, fibrates don't offer clear-cut benefits.

There have been two recent projects that looked at the drugs. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial looked at 10,000 people. Those in the group who took simvastatin (Zocor) and fenofibrate didn't have particularly different outcomes from those who took only simvastatin.

The second study, the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, had nearly as many participants as ACCORD. It looked only at fibrates and found that they didn't do any better than placebos at reducing heart disease deaths.

Doctors have had mixed reactions to the recent science.

Fibrates have "a lot of promise, but so far that promise is unfulfilled," said Dr. Cam Patterson of the Center for Heart and Vascular Care at the University of North Carolina, Chapel Hill. "Statins are the only cholesterol-lowering drugs that have been shown conclusively to save lives," Patterson told ABC. "Fibrates may be an option as add-on therapy, but there is no compelling case to use them as first-line therapy."

Some doctors said that lowering triglycerides---a strength of fibrates---could be important in treating obese patients. Others said that the drugs could be useful in patients who have trouble handling statins. Still others called for further research.

Sources:

ABC News
JAMA

Click Here To View Or Post Comments

Categories: ACCORD/Action to Control Cardiovascular Risk in Diabetes, Cholesterol-lowering, Diabetes, Diabetes, First-line therapy, Medications, ournal of the American Medical Association, Pfizer


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jun 25, 2013

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.